Fentanyl iontophoretic transdermal system: Phase III started

SymBio began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate SyB P-1501 in about 312 patients. Patients can self-administer up to 6 doses of 40 ug of fentanyl every hour, with up to 80 doses daily for up to 3 days. The product is approved in the U.S. and EU as Ionsys fentanyl iontophoretic transdermal system. ...